Skip to main content
. Author manuscript; available in PMC: 2017 Mar 21.
Published in final edited form as: Vitam Horm. 2016 Mar 21;101:175–196. doi: 10.1016/bs.vh.2016.02.002

Table 1.

Metabolic microRNAs currently in development as drug targets

microRNA Validated
Target Genes		 Function (Key Ref) Anti-miR Drugs
miR-122 Agpat1, Mogat1
MTTP, Klf6		 Increase hepatic TG level and
HCC development (Hsu et al; Tsai
et al)		 RG-101 for
Hepatitis C virus
Infection
miR-33 SREBP, HMGCR,
LDL-R, ABCA1,
ABCG1		 Control cholesterol homeostasis
(Esau, C. C et. al; Rayner, K. J. et.
al; Najafi-Shoushtari et. al.)		 SPC-4955 for
Cholesterol, HDL &
Cardiovascular
diseases
miR-103/107 caveolin-1 Regulate glucose homeostasis,
insulin sensitivity (Trajkovski, M
et. al.)		 RG-125
(AZD4076) for
NASH in T2D
patients/pre-
diabetes
miR-378 MED13 Mitochondrial metabolism
(Carrer et al.)		 Obesity,
Cardiovascular
Disease
miR-208 Myh6, Myh7,
Thrap1,
Myostatin,
MED13		 Cardiac hypertrophy (Callis et.
al.; Montgomery et. al; Grueter
et.al.)		 Obesity,
Cardiovascular
Disease
miR-221 DDIT4, CDKN1,
p27, p57,		 Cell cycle arrest, Cell
proliferation (Fornari et al.
Pineaua et al.)		 Hepatocelluar
Carcinoma
miR-21 PTEN Cell proliferation, Cell cycle
arrest, Apoptosis (Meng et al. )		 RG-012 for
Hepatocelluar
Carcinoma